Dr. Darin D. Dougherty, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 13
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
MA license 80968
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 83
- Patients’ average age
- 45
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 69 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 11 payments worth $1,964 in total to this clinician.
| Neurocrine Biosciences, Inc. | $1,964 |
|---|
| Travel and Lodging | $1,573 |
|---|---|
| Food and Beverage | $391 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurocrine Biosciences, Inc. Oct 3, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $744 |
| Neurocrine Biosciences, Inc. Oct 30, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $269 |
| Neurocrine Biosciences, Inc. Oct 3, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $223 |
| Neurocrine Biosciences, Inc. Oct 4, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $223 |
| Neurocrine Biosciences, Inc. Oct 3, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $60,814 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - NCT06423430--Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Abbott Laboratories - Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderlin…
Boehringer Ingelheim International GmbH - A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
AbbVie Inc. · Terminated · NCT05941442 - A phase 3, multicenter, randomized, double-blind study to investigate the efficacy and safety of brenipatide compared with placebo for the treatment of adult participants with alcohol use disorder (renew-ALC-2)
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.